Jacobson Pharma Corporation Limited Pharma Corporation 雅 各 臣 科 研 製 藥 有 限 公 司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號：2633) NOTIFICATION LETTER 通知信函 16 December 2024 Dear Non-registered Shareholder(s)(Note 1), Jacobson Pharma Corporation Limited (the "Company") – Notice of publication of 2024/2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are available on the Co ...

Jacobson Pharma Corporation Limited Pharma Corporation 雅 各 臣 科 研 製 藥 有 限 公 司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號：2633) NOTIFICATION LETTER 通知信函 16 December 2024 Dear Registered Shareholder(s), Jacobson Pharma Corporation Limited (the "Company") – Notice of publication of 2024/2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are now available on the Company's ...

Financial Performance - Revenue from continuing operations for the six months ended September 30 was HKD 810,002 thousand, an increase of 13.3% compared to HKD 714,918 thousand in the previous period[6]. - Gross profit for the same period was HKD 351,471 thousand, reflecting a growth of 16.7% from HKD 301,079 thousand[6]. - Adjusted EBITDA from continuing operations reached HKD 272,185 thousand, up 24.8% from HKD 218,120 thousand[6]. - The company reported a net profit attributable to equity holders of HKD 140,290 thousand, down 8.9% from HKD 154,040 thousand[6]. - The gross profit margin improved to 43.4% from 42.1% in the previous period[6]. - Profit from continuing operations for the same period rose significantly by 44.2% to HKD 140.3 million, driven by strong performance in both public and private sectors[24]. - The group reported a consolidated profit before tax of HKD 175,377 thousand for the six months ended September 30, 2024, compared to HKD 118,860 thousand in the same period of 2023, indicating a significant increase of approximately 47.5%[174]. - The company reported a profit attributable to equity holders of HKD 140,290,000 for the six months ended September 30, 2024, compared to HKD 154,040,000 in the previous year[189]. Assets and Liabilities - Total assets as of September 30, 2024, amounted to HKD 3,606,697 thousand, a 3.4% increase from HKD 3,486,854 thousand[6]. - Total liabilities increased by 5.5% to HKD 1,150,942 thousand from HKD 1,090,494 thousand[6]. - The net debt-to-equity ratio decreased significantly from 12.2% at the end of the previous fiscal year to 5.6%, indicating improved financial stability[24]. - Cash reserves remained resilient, totaling HKD 515.9 million at the end of the reporting period, showcasing the company's operational discipline[24]. - The company’s equity attributable to equity holders increased to HKD 2,431,536 thousand from HKD 2,372,141 thousand, reflecting a growth of 2.5%[150]. Market and Product Development - The company aims to expand into new areas through innovative solutions and strategic R&D investments[11]. - The company is strategically focusing on expanding its product portfolio, particularly in specialty drugs and biosimilars, to capture fast-growing market segments[16]. - The cardiovascular product line, including Eplerenone, Lisinopril, and Atenolol, achieved significant sales growth due to successful public procurement, contributing to the overall strong performance of the group[28]. - The group launched new products such as Sildenafil Tablet 20mg, Cyanocobalamin Tablet 50mcg, and Amlodipine Oral Solution, and received registration approval for 15 additional new products, enhancing its ability to meet diverse healthcare needs[29]. - As of September 30, 2024, the product pipeline expanded to 193 products, with 65 approved, 14 awaiting approval, and 58 in stability preparation or research stages, demonstrating the group's commitment to long-term growth[30]. Strategic Initiatives - The company is actively exploring partnerships with local and overseas R&D institutions to develop innovative drug manufacturing technologies[16]. - The group plans to collaborate with SDK Therapeutics Inc. for Phase 3 clinical trials in the U.S. and EU, aiming to improve treatment standards for acute promyelocytic leukemia by transitioning from intravenous to oral administration[37]. - The group signed multiple exclusive licensing agreements to enhance its product portfolio in cardiovascular health, diabetes management, and allergy treatment, including a new anticoagulant for thrombus prevention and treatment[35]. Corporate Governance and Compliance - The company has complied with all applicable laws and regulations during the reporting period, with no significant regulatory non-compliance issues reported[96]. - The audit committee, consisting of three independent non-executive directors, oversees the company's financial reporting and internal control systems[103]. - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[99]. Shareholder Information - The company declared an interim dividend of HKD 0.035 per share, totaling approximately HKD 70 million, compared to HKD 0.025 per share for the same period last year[107]. - Major shareholders include Mr. Chan with a beneficial interest in 1,191,638,000 shares, representing 59.58% of the company[120]. - The stock option plan allows for a maximum of 138,000,000 shares to be issued, equivalent to approximately 6.90% of the issued shares as of the report date[126]. Economic Outlook - The Hong Kong economy is expected to grow by 1.8% year-on-year in Q3 2024, although growth has slowed down due to geopolitical tensions and weak private consumption[42]. - The non-patent drug market is projected to grow due to increased government healthcare investments and the introduction of chronic disease management programs[42].

EF001 | 其他信息 | | | --- | --- | | 其他信息 | 不適用 | | 發行人董事 | | | 於 本 公 告 日 期，董 事 會 由 執 行 董 事 岑 廣 業 先 生（亦 為 主 席 兼 行 政 總 裁）、嚴 振 亮先 生 及 潘 裕 慧 女 士；非 執 行 董 | | | 事 黃 志 基 教 授；及 獨 立 非 執 行 董 事 林 烱 堂 醫 生、楊 俊 文 先 生 及 林 誠 光 教 授 組 成。 | | 第 2 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 雅各臣科研製藥有限公司 | | 股份代號 | 02633 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二四年九月三十日止六個月的中期股息 | | 公告 ...

Financial Performance - Revenue from continuing operations for the six months ended September 30, 2024, was approximately HKD 810.0 million, an increase of about 13.3% compared to HKD 714.9 million in the same period of 2023[3]. - Operating profit from continuing operations for the same period was approximately HKD 195.8 million, up about 18.0% from HKD 166.0 million in 2023[3]. - Profit from continuing operations for the six months was approximately HKD 140.3 million, representing a significant increase of about 44.2% from HKD 97.3 million in the previous year[3]. - Gross profit for the six months ended September 30, 2024, was HKD 351.5 million, compared to HKD 301.1 million in 2023, reflecting a growth in gross margin[5]. - The total comprehensive income for the period was HKD 115.8 million, down from HKD 172.7 million in the same period last year[11]. - Basic and diluted earnings per share from continuing operations were HKD 7.07, compared to HKD 5.09 in the previous year[17]. - The company reported a comprehensive profit before tax of HKD 175,377,000, compared to HKD 118,860,000 in 2023[35]. - Profit attributable to equity holders slightly decreased by HKD 13.7 million or 8.9% to HKD 140.3 million, mainly due to the spin-off of a subsidiary on August 24, 2023, which resulted in a reduction of attributable profit[131]. Dividends and Shareholder Returns - The board declared an interim dividend of HKD 0.035 per share, totaling approximately HKD 70.0 million, which is an increase of about 40.0% from HKD 0.025 per share (totaling approximately HKD 48.4 million) in the same period last year[3]. - Basic earnings per share increased to HKD 70,008,000 for the six months ended September 30, 2024, up from HKD 48,356,000 in the previous year, reflecting a growth of 44.8%[53]. - The company declared a special dividend on August 1, 2023, distributing shares of a subsidiary to equity holders, marking the end of its involvement in the branded healthcare business[66]. Assets and Liabilities - Total assets as of September 30, 2024, were HKD 2,524.7 million, slightly up from HKD 2,522.4 million as of March 31, 2024[19]. - The company's net asset value increased to HKD 2,455.8 million from HKD 2,396.4 million in the previous period[22]. - The company’s total liabilities increased to HKD 301,656,000 as of September 30, 2024, compared to HKD 216,467,000 as of March 31, 2024, indicating a significant rise in obligations[57]. - The company’s deferred tax liabilities decreased to HKD (1,757,000) for the six months ended September 30, 2024, from HKD (6,810,000) in the previous year[36]. Revenue Segments - For the six months ending September 30, 2024, the reported revenue from the non-patented drug segment was HKD 810,002 thousand, an increase from HKD 714,918 thousand in the same period of 2023, representing a growth of approximately 13.3%[33]. - The brand healthcare segment reported no revenue for the current period, as the company has ceased operations in this segment[32]. - Revenue from external customers in Hong Kong was HKD 769,417,000, representing a 11.9% increase from HKD 687,837,000 in 2023[35]. - Revenue from mainland China significantly increased by HKD 10.5 million or 66.0%, mainly due to increased demand for cold and flu products[118]. Cost Management - The company reported a significant reduction in financing costs, decreasing from HKD 47.4 million to HKD 20.5 million[5]. - Employee costs totaled HKD 243.4 million, up from HKD 215.4 million in the previous six months, reflecting the need to support the group's growth and development[108]. - The cost of sales increased by HKD 44.7 million or 10.8%, consistent with the overall sales growth during the reporting period[122]. - Material costs accounted for approximately 44% of total sales costs, while employee costs and other production costs accounted for 34% and 22%, respectively[122]. Strategic Focus and Development - The company continues to focus on the development, production, marketing, and sales of non-patented drugs, primarily in Hong Kong[30]. - The financial performance for the six months ending September 30, 2024, reflects the company's strategic focus on its core business of non-patented drugs[30]. - The company is committed to sustainable development, focusing on environmental management and social responsibility initiatives[76]. - The aging population and rising chronic diseases continue to drive long-term demand for medical consultations and medications[81]. Product Development and Innovation - The company expanded its product portfolio by launching new products such as Sildenafil Tablet 20mg, Cyanocobalamin Tablet 50mcg, and Amlodipine Oral Solution, with 15 new products receiving registration approval for market launch[84]. - As of September 30, 2024, the product pipeline has expanded to 193 products, with 65 products registered, 14 awaiting approval, and 58 in stability preparation or research stages, reflecting the company's commitment to long-term growth[86]. - The company has established a licensing agreement with a US firm focused on hematology and oncology, which is crucial for accelerating the clinical development of Arsenol Oral Solution as a rare disease drug with the FDA[94]. Corporate Governance and Compliance - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[161]. - The audit committee, consisting of three independent non-executive directors, is responsible for reviewing and supervising the company's financial reporting procedures and internal controls[165]. - The company adhered to all applicable laws and regulations that significantly impact its operations during the reporting period[160]. Future Outlook - The company provided an optimistic outlook, projecting a revenue growth of 20% for the next fiscal year[176]. - New product launches are expected to contribute an additional HKD 300 million in revenue, with a focus on health and wellness sectors[176]. - Market expansion plans include entering two new regions, which are projected to generate an additional HKD 500 million in revenue[176].

香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因本聯合公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何 損 失 承 擔 任 何 責 任。 Pharma Corporation Jacobson Pharma Corporation Limited 雅 各 臣 科 研 製 藥 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2633） JBM (Healthcare) Limited 健倍 苗 苗 ( 保健 ) 有 限 公司 （於開曼群島註冊成立的有限公司） （股份 代號：2161） 聯合公告 有關買賣 李衆勝堂（集 團）有限公司 股份的關連交易 買賣李衆勝堂（集 團）有限公司股份 於二零二四年十一月十一日（交 易 時 段 後），Po Chai Herbal 及 PCHT（作 為 賣 方）與歐化藥業（作 為 買 方）訂 立 買 賣 協 議，據 此，Po Chai Herbal 及 PCHT 有 條 件同意分別出售56,500股 及44,000股 銷 售 ...

（股份代號：2633） 董事會召開日期 雅各臣科研製藥有限公司（「本公司」）董事會（「董事會」）兹通告謹定於二零二四 年十一月二十一日（星 期 四）舉 行 董 事 會 會 議，藉 以 考 慮 及 通 過 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 四 年 九 月 三 十 日 止 的 六 個 月 中 期 業 績 以 供 發 佈，並 考 慮 派 發 中期股息（如 有），以 及 處 理 其 他 事 項。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Pharma Corporation Jacobson Pharma Corporation Limited 雅 各 臣 科 研 製 藥 有 限 公 司 （於開曼群島註冊成立的有限公司） 公司秘書 余振球 香 港，二 零 二 四 年 十 一 月 八 日 於 本 公 告 日 期，董 事 會 由 執 行 董 事 岑 廣 業 先 生（亦 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Pharma Corporation Jacobson Pharma Corporation Limited 雅 各 臣 科 研 製 藥 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2633） 盈喜預告 本公告由雅各臣科研製藥有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及香港 法例第571章證券及期貨條例第XIVA部項下內幕消息條文（定 義 見 上 市 規 則）刊 發。 本公司董事（「董 事」）會（「董事會」）謹此告知本公司股東（「股 東」）及 潛 在 投 資 者， 基於對本集團截至二零二四年九月三十日止六個月（「中期期間」）的未經審核 綜 合 管 理 賬 目 的 初 步 審 閱 及 董 事 會 目 前 可 得 的 資 料，本 ...

財務摘要 0 500,000 1,000,000 1,500,000 2,000,000 2,500,000 3,000,000 3,500,000 二零二一 財年 二零二二 財年 二零二三 財年 二零二四 財年(1) 二零二零 財年 資產淨值 （千港元） 於二零二四年 (3) 來自持續經營業務的經調整EBITDA率根據來自持續經營業務的經調整EBITDA除以來自持續經營業務的收益再乘以100%計算得出。 各位股東： 致力卓越營運 展望未來，儘管我們預期在疫情後將會逐步復甦，但我們深知目前的 地緣政治緊張局勢及動盪對當前的經濟帶來不明朗因素。雖然我們意 識到市場上的種種逆境，但對經濟長期韌性及非專利藥市場以至更廣 泛的醫療保健行業的增長潛力仍然抱持樂觀態度。我們致力在這個日 新月異的時局中培養我們的企業適應力及靈活性，為可持續發展奠下 堅實的基礎。 最後，本人謹代表董事會向我們的僱員、合作夥伴和股東致以衷心的 感謝。你們堅定不移的支持和貢獻，為我們致力提供可及、優質的醫 療解決方案，並為所有持份者創造可持續價值的旅程帶來關鍵助力。 二零二四年六月二十日 | --- | --- | --- | |------- ...

Financial Performance - For the fiscal year ending March 31, 2024, revenue from continuing operations was approximately HKD 1,467.8 million, an increase of about 15.8% compared to HKD 1,267.6 million in the same period of 2023[1]. - Operating profit from continuing operations for the same fiscal year was approximately HKD 333.1 million, up about 17.2% from the adjusted operating profit of HKD 284.3 million in 2023[1]. - Profit for the year was approximately HKD 290.8 million, representing a 14.4% increase from the adjusted profit of HKD 254.1 million in the previous year[1]. - The company's total comprehensive income attributable to equity holders from continuing operations for the year ended March 31, 2024, was HKD 193,815, a decrease of 38.6% compared to HKD 315,570 for the same period in 2023[23]. - The reported segment revenue for the year ended March 31, 2024, was HKD 1,467,814,000, representing an increase of 15.7% compared to HKD 1,267,868,000 for the previous year[64]. - The adjusted EBITDA for the reporting segments was HKD 453,079,000 for the year ended March 31, 2024, compared to HKD 444,173,000 for the previous year, reflecting a growth of 2%[64]. - The company reported a profit attributable to equity holders of HKD 210,236,000 from continuing operations for the year ended March 31, 2024, compared to HKD 207,513,000 for the previous year[70]. - The company’s total comprehensive income for the year ended March 31, 2024, was HKD 254,583,000, compared to HKD 250,345,000 for the previous year, showing a modest increase[65]. - The company’s effective tax rate for the year was maintained at 16.5%, consistent with the previous year[68]. Dividends - The board proposed a final dividend of HKD 0.03 per share, totaling approximately HKD 60.0 million, compared to a final dividend of HKD 0.0238 per share in 2023[1]. - The proposed final dividend per share is HKD 3.00 for the year ended March 31, 2024, compared to HKD 2.38 for the previous year, indicating an increase of 26.1%[74]. - The company distributed a special dividend of 492,259,244 shares of Jianbei Miao Miao, equivalent to approximately HKD 29.52 per share based on the closing price of HKD 1.16 on August 24, 2023[77]. Assets and Liabilities - Non-current assets totaled HKD 2,522.4 million, a decrease from HKD 3,623.1 million in the previous year[5]. - Current assets decreased to HKD 591.6 million from HKD 1,100.98 million in the previous year[5]. - Total equity decreased to HKD 2,396.4 million from HKD 3,256.5 million in the previous year[6]. - Cash and cash equivalents were HKD 411.9 million, down from HKD 1,036.4 million in the previous year[5]. - Non-current liabilities decreased significantly to HKD 717,651 as of March 31, 2024, from HKD 1,467,542 in 2023, a reduction of 51.1%[26]. - The net asset value of the company was HKD 2,396,360 as of March 31, 2024, down from HKD 3,256,522 in 2023, indicating a decline of 26.4%[26]. - The company’s total liabilities decreased to HKD 1,467,542 in 2024 from HKD 2,234,000 in 2023, indicating a reduction of 34.4%[26]. Operations and Market Presence - The company is primarily engaged in the development, production, marketing, and sale of non-patent drugs, with operations mainly in Hong Kong[7]. - The brand healthcare segment's performance has been classified as discontinued operations for the fiscal year ending March 31, 2024[4]. - The company has ceased operations in the brand medical healthcare business, classifying it as a discontinued operation[85]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[67]. - The company is optimistic about future growth, focusing on expanding its product portfolio and enhancing R&D capabilities[94]. - The company is developing an innovative e-business platform tailored for private clinics, which has received positive feedback and shows promising adoption rates[124]. - The company has expanded distribution agreements in selected Southeast Asian countries, including a signed agreement with Malaysia, and is considering clinical trials in the UK, Netherlands, and the US[179]. Research and Development - Research and development costs, excluding capitalized development costs, were HKD 6,450 for the year ended March 31, 2024, compared to HKD 1,166 in 2023, showing a significant increase[44]. - The R&D pipeline includes 185 products at various development stages, with 64 products already registered and 12 submitted for approval[145]. - The company successfully submitted 12 products for approval, enhancing its product pipeline and future market offerings[94]. - The company obtained exclusive rights to six effective specialty drugs across various fields, including gastrointestinal diseases and oncology, enhancing its product portfolio and driving continuous growth[123]. Employee and Operational Costs - Employee costs rose by HKD 42.6 million or 18.0%, reflecting the need for increased production to meet product demand[170]. - The group employed 1,723 employees as of March 31, 2024, compared to 1,484 employees as of March 31, 2023, indicating a strategic increase in workforce[189]. - The group provides various employee benefits, including annual leave, mandatory provident fund, group medical insurance, and life insurance[189]. - The company maintains a strong focus on employee recruitment, development, and retention, offering competitive compensation and training programs[161]. Market Trends and Demand - The demand for basic and specialty pharmaceuticals increased due to the recovery of social activities post-pandemic[105]. - The increase in flu cases, particularly among children and the elderly, has driven demand for cold and flu medications, resulting in growth in both public and private sector businesses during the reporting period[132]. - The aging population with complex health needs is driving the demand for chronic disease management medications, aligning with the value proposition of the non-patent drug market[184]. - The economic recovery in Hong Kong post-COVID-19 has led to a significant increase in inbound tourism and consumer spending, contributing to strong performance since Q1 2023[128]. Strategic Initiatives - The company’s strategic execution has resulted in substantial achievements and effective cost management[122]. - The collaboration with Fosun Kite Biotechnology for the CAR-T cell therapy Yescarta aims to enhance treatment options for specific types of lymphoma[151]. - The initial pilot phase of the medical e-business system has yielded positive results, reflected in good user feedback and excellent adoption rates[181]. - The platform provides unparalleled convenience for medical professionals and key customers, facilitating easy access to the product range and streamlining the ordering process[182].